Brain atrophy has emerged as a clinically relevant component of disease progression in
multiple sclerosis. Progressive loss of brain tissue bulk can be detected in vivo in a sensitive …

Patients with multiple sclerosis acquire disability either through relapse-associated worsening
(RAW) or progression independent of relapse activity (PIRA). This study addresses the …

Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta -
Bermel - 2013 - Annals of Neurology - Wiley Online Library … Bermel MD… Bermel MD …

… (Mr Bermel and Dr Bakshi); drafting of the manuscript (Mr Bermel and … Bermel and Drs
Bakshi and Jacobs); statistical expertise (Mr Bermel and Dr Bakshi); obtaining funding (Mr Bermel …

Background There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits
several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and …

Context While gray matter T2 hypointensity in multiple sclerosis (MS) has been associated
with physical disability and clinical course, previous studies have relied on visual magnetic …

Background: Cognitive dysfunction is common in multiple sclerosis (MS) patients and has
important consequences for daily activities, yet, unlike motor function, is not routinely assessed …

Disease-modifying drugs are initiated early and continued for years in patients with multiple
sclerosis. Long-term tolerability and impact are not known. The objective of this study was to …

Objectibe. Brain atrophy may occur early in the course of multiple sclerosis (MS) and may
be associated with disability. Brain magnetic resonance imaging (MRI) of 114 MS patients (…

Brain atrophy is a proposed MRI marker of irreversible pathologic damage in multiple sclerosis
(MS). The brain parenchymal fraction (BPF) is the ratio of brain parenchymal volume to …